You are here: Home » Companies » News
Business Standard

ITC starts clinical trials of nasal spray for Covid-19 prevention

The company plans to market the nasal spray under the Savlon brand once it gets all the requisite regulatory approvals, according to sources

Topics
ITC | Coronavirus

Press Trust of India  |  New Delhi 

ITC
Photo: Shutterstock

Diversified entity on Thursday confirmed that it is developing a nasal spray for COVID-19 prevention for which it has initiated clinical trials.

Developed by scientists at Life Sciences and Technology Centre (LSTC), Bengaluru, the company plans to market the nasal spray under the Savlon brand once it gets all the requisite regulatory approvals, according to sources.

When contacted for comments, a spokesperson of said, "We are unable to share more details at the current moment as the clinical trials are underway."

The spokesperson declined to comment on a detailed query on where is the clinical trial being done, from where the commercial production would be done when approved and under what brand the nasal spray would be marketed.

However, sources said the company had received approvals from ethics committees and is registered with Clinical Trial Registry-India (CTRI) for clinical trials of the nasal spray which is designed to arrest the virus at the entry point in the nasal cavity itself.

They further said the product has the potential to be effective and safe in preventing infection and transmission of COVID-19 along with the existing measures of hygiene recommended by health authorities.

ITC's LSTC has been at the core of the company's drive for science led product innovation to support and build its wide range of product portfolio.

The company's R&D teams were instrumental in developing a range of innovative health and hygiene offerings that were commercially made available under the Savlon brand, during the pandemic.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, November 25 2021. 13:30 IST
RECOMMENDED FOR YOU
.